Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2004 2
2005 5
2006 3
2007 1
2009 4
2010 5
2011 11
2012 11
2013 6
2014 11
2015 5
2016 4
2017 6
2018 3
2019 2
2020 2
2021 8
2022 7
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Distinct use of super-enhancer elements controls cell type-specific CD25 transcription and function.
Spolski R, Li P, Chandra V, Shin B, Goel S, Sakamoto K, Liu C, Oh J, Ren M, Enomoto Y, West EE, Christensen SM, Wan ECK, Ge M, Lin JX, Yan B, Kazemian M, Yu ZX, Nagao K, Vijayanand P, Rothenberg EV, Leonard WJ. Spolski R, et al. Among authors: enomoto y. Sci Immunol. 2023 Nov 3;8(89):eadi8217. doi: 10.1126/sciimmunol.adi8217. Epub 2023 Nov 3. Sci Immunol. 2023. PMID: 37922339 Free PMC article.
Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T, Chinen T, Nishiyama A, Asada S, Shimura R, Isobe T, Yamamoto K, Sato N, Enomoto Y, Tanaka Y, Fukuyama T, Satoh H, Kato K, Saitoh K, Ishikawa T, Soga T, Nannya Y, Fukagawa T, Nakanishi M, Kitagawa D, Kitamura T, Goyama S. Yabushita T, et al. Among authors: enomoto y. Cell Rep. 2023 Sep 26;42(9):113098. doi: 10.1016/j.celrep.2023.113098. Epub 2023 Sep 14. Cell Rep. 2023. PMID: 37714156 Free article.
The molecular basis of myeloid malignancies.
Kitamura T, Inoue D, Okochi-Watanabe N, Kato N, Komeno Y, Lu Y, Enomoto Y, Doki N, Uchida T, Kagiyama Y, Togami K, Kawabata KC, Nagase R, Horikawa S, Hayashi Y, Saika M, Fukuyama T, Izawa K, Oki T, Nakahara F, Kitaura J. Kitamura T, et al. Among authors: enomoto y. Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(10):389-404. doi: 10.2183/pjab.90.389. Proc Jpn Acad Ser B Phys Biol Sci. 2014. PMID: 25504228 Free PMC article. Review.
For which thoracic operation is U-VATS superior?
Hirai K, Enomoto Y, Usuda J. Hirai K, et al. Among authors: enomoto y. J Vis Surg. 2017 Aug 21;3:103. doi: 10.21037/jovs.2017.07.06. eCollection 2017. J Vis Surg. 2017. PMID: 29078664 Free PMC article. Review.
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab.
Taguchi S, Kawai T, Buti S, Bersanelli M, Uemura Y, Kishitani K, Miyakawa J, Sugimoto K, Nakamura Y, Niimi F, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Taguchi S, et al. Among authors: enomoto y. Immunotherapy. 2023 Aug;15(11):827-837. doi: 10.2217/imt-2023-0028. Epub 2023 May 16. Immunotherapy. 2023. PMID: 37191002
Hyperactive Natural Killer cells in Rag2 knockout mice inhibit the development of acute myeloid leukemia.
Sugimoto E, Li J, Hayashi Y, Iida K, Asada S, Fukushima T, Tamura M, Shikata S, Zhang W, Yamamoto K, Kawabata KC, Kawase T, Saito T, Yoshida T, Yamazaki S, Kaito Y, Imai Y, Denda T, Ota Y, Fukuyama T, Tanaka Y, Enomoto Y, Kitamura T, Goyama S. Sugimoto E, et al. Among authors: enomoto y. Commun Biol. 2023 Dec 21;6(1):1294. doi: 10.1038/s42003-023-05606-3. Commun Biol. 2023. PMID: 38129572 Free PMC article.
Cytokine-enhanced cytolytic activity of exosomes from NK Cells.
Enomoto Y, Li P, Jenkins LM, Anastasakis D, Lyons GC, Hafner M, Leonard WJ. Enomoto Y, et al. Cancer Gene Ther. 2022 Jun;29(6):734-749. doi: 10.1038/s41417-021-00352-2. Epub 2021 Jul 27. Cancer Gene Ther. 2022. PMID: 34316033 Free PMC article.
Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
Taguchi S, Kawai T, Ambe Y, Kishitani K, Sugimoto K, Miyakawa J, Nakamura Y, Noda M, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Furuya Y, Sato Y, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Taguchi S, et al. Among authors: enomoto y. Int J Urol. 2023 Dec;30(12):1180-1186. doi: 10.1111/iju.15300. Epub 2023 Sep 22. Int J Urol. 2023. PMID: 37740409
Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD).
Kitamura T, Watanabe-Okochi N, Enomoto Y, Nakahara F, Oki T, Komeno Y, Kato N, Doki N, Uchida T, Kagiyama Y, Togami K, Kawabata KC, Nishimura K, Hayashi Y, Nagase R, Saika M, Fukushima T, Asada S, Fujino T, Izawa Y, Horikawa S, Fukuyama T, Tanaka Y, Ono R, Goyama S, Nosaka T, Kitaura J, Inoue D. Kitamura T, et al. Among authors: enomoto y. J Biochem. 2016 Jan;159(1):17-25. doi: 10.1093/jb/mvv114. Epub 2015 Nov 20. J Biochem. 2016. PMID: 26590301 Free PMC article. Review.
CHIP-associated mutant ASXL1 in blood cells promotes solid tumor progression.
Liu X, Sato N, Shimosato Y, Wang TW, Denda T, Chang YH, Yabushita T, Fujino T, Asada S, Tanaka Y, Fukuyama T, Enomoto Y, Ota Y, Sakamoto T, Kitamura T, Goyama S. Liu X, et al. Among authors: enomoto y. Cancer Sci. 2022 Apr;113(4):1182-1194. doi: 10.1111/cas.15294. Epub 2022 Feb 26. Cancer Sci. 2022. PMID: 35133065 Free PMC article.
93 results